You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
Title |
In vivo efficacy of artemether-lumefantrine and artesunate-amodiaquine for the treatment of uncomplicated falciparum malaria in children: a multisite, open-label, two-cohort, clinical trial in Mozambique
|
---|---|
Published in |
Malaria Journal, August 2014
|
DOI | 10.1186/1475-2875-13-309 |
Pubmed ID | |
Authors |
Abel Nhama, Quique Bassat, Sónia Enosse, Arsenio Nhacolo, Rosália Mutemba, Eva Carvalho, Eva Naueia, Esperança Sevene, Caterina Guinovart, Marian Warsame, Sergi Sanz, Abdul Mussa, Graça Matsinhe, Pedro Alonso, Armindo Tiago, Eusebio Macete |
Abstract |
Mozambique adopted artemisinin-based combination therapy (ACT) for the treatment of uncomplicated Plasmodium falciparum malaria in the year 2006, and since 2009 artemether-lumefantrine (AL) and artesunate-amodiaquine (ASAQ) have been proposed as alternative first-line treatments. A multicentre study was conducted in five sites across the country to assess the in vivo efficacy and tolerability of these two drugs. |
X Demographics
The data shown below were collected from the profiles of 4 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
Country | Count | As % |
---|---|---|
United Kingdom | 1 | 25% |
Unknown | 3 | 75% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 3 | 75% |
Science communicators (journalists, bloggers, editors) | 1 | 25% |
Mendeley readers
The data shown below were compiled from readership statistics for 72 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
Country | Count | As % |
---|---|---|
United Kingdom | 2 | 3% |
Spain | 1 | 1% |
France | 1 | 1% |
Unknown | 68 | 94% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Researcher | 17 | 24% |
Student > Ph. D. Student | 10 | 14% |
Student > Master | 10 | 14% |
Other | 5 | 7% |
Student > Doctoral Student | 4 | 6% |
Other | 12 | 17% |
Unknown | 14 | 19% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 21 | 29% |
Agricultural and Biological Sciences | 11 | 15% |
Social Sciences | 4 | 6% |
Biochemistry, Genetics and Molecular Biology | 3 | 4% |
Unspecified | 3 | 4% |
Other | 11 | 15% |
Unknown | 19 | 26% |
Attention Score in Context
This research output has an Altmetric Attention Score of 3. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 14 August 2014.
All research outputs
#13,864,911
of 23,925,854 outputs
Outputs from Malaria Journal
#3,390
of 5,755 outputs
Outputs of similar age
#109,427
of 233,923 outputs
Outputs of similar age from Malaria Journal
#60
of 116 outputs
Altmetric has tracked 23,925,854 research outputs across all sources so far. This one is in the 41st percentile – i.e., 41% of other outputs scored the same or lower than it.
So far Altmetric has tracked 5,755 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 6.9. This one is in the 39th percentile – i.e., 39% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 233,923 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 52% of its contemporaries.
We're also able to compare this research output to 116 others from the same source and published within six weeks on either side of this one. This one is in the 49th percentile – i.e., 49% of its contemporaries scored the same or lower than it.